Booze R M, Wallace D R
Department of Pharmacology, University of Kentucky College of Medicine, Lexington 40536-0084.
Synapse. 1995 Jan;19(1):1-13. doi: 10.1002/syn.890190102.
A novel dopamine receptor mRNA transcript has been identified and classified as the D3 receptor subtype. We have examined the binding of the D2/D3-selective compound [125I]-Iodosulpride using unlabeled D3-selective 7-OH-DPAT to determine the distribution of D2 and D3 dopamine receptor subtypes in the rat basal forebrain. Use of [125I]-labeled ligands has significant advantages over [3H]-labeled compounds for autoradiographic studies, especially for evaluating small brain areas containing low receptor densities. [125I]-Iodosulpride identified two sites with high affinity (< 1 nM) in the presence of (-)sulpiride (1 microM; D2+3) or 7-OH-DPAT (10 nM; D3), with a greater density of D2 receptors (twofold) compared to D3 receptors in the striatum. The density of D2 and D3 receptor subtypes displayed a 1:1 ratio in the nucleus accumbens. [125I]-Iodosulpride with 7-OH-DPAT displayed D2 sites, predominately in the striatum. Digital subtraction autoradiography showed the highest levels of D3 binding in the islands of Calleja as well as in the core and shell regions of the nucleus accumbens. In sum, the advantages in using [125I]-Iodosulpride to label the dopamine receptor subtypes are high specific activity, affinity, and lack of quenching in autoradiographic analyses. Moreover, masking D3 receptors with 7-OH-DPAT permitted indirect determination of D3 receptor density and localization using the [125I]-labeled ligand, without the potential confound of 7-OH-DPAT binding to sigma receptors. The colocalization of the D2 dopamine receptors with D3 receptors suggests that unique interactions may exist between the receptor subtypes in the rat basal forebrain region.
一种新的多巴胺受体mRNA转录本已被鉴定并归类为D3受体亚型。我们使用未标记的D3选择性化合物7-羟基-二丙基氨基四氢吡啶(7-OH-DPAT)检测了D2/D3选择性化合物[125I]-碘舒必利的结合情况,以确定大鼠基底前脑中D2和D3多巴胺受体亚型的分布。在放射自显影研究中,使用[125I]标记的配体比[3H]标记的化合物具有显著优势,特别是对于评估含有低受体密度的小脑区。在存在(-)舒必利(1μM;D2+3)或7-OH-DPAT(10 nM;D3)的情况下,[125I]-碘舒必利在纹状体中鉴定出两个高亲和力(<1 nM)的位点,D2受体密度比D3受体高两倍。伏隔核中D2和D3受体亚型的密度显示为1:1比例。[125I]-碘舒必利与7-OH-DPAT显示出D2位点,主要在纹状体中。数字减法放射自显影显示,在Calleja岛以及伏隔核的核心和壳区域中,D3结合水平最高。总之,使用[125I]-碘舒必利标记多巴胺受体亚型的优势在于高比活性、亲和力以及在放射自显影分析中无淬灭现象。此外,用7-OH-DPAT掩盖D3受体允许使用[125I]标记的配体间接测定D3受体密度和定位,而不存在7-OH-DPAT与σ受体结合带来的潜在混淆。D2多巴胺受体与D3受体的共定位表明,大鼠基底前脑区域的受体亚型之间可能存在独特的相互作用。